Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Second View: Discussing the two-year data from the phase 3 BE MOBILE 1 and BE MOBILE 2 clinical trials of BIMZELX arthritis presented at EULAR 2024

Ticker(s): UCBJY

Who's the expert?

Institution: Private Practice

Rheumatologist with a speciality in autoimmune diseases.
Currently manages 45 patients per month with Lupus Nephritis and 65 patients (total) with ANCA-Associated Vasculitis.
Over 20 years of experience and board certified in Rheumatology.

Interview Goal

to discuss the current treatment landscape and the potential of BIMZELX (bimekizumab-bkzx) an IL-17 inhibitor being developed by UCB for the treatment of arthritis.

Do you want answers to these questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.